JP2014515751A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014515751A5 JP2014515751A5 JP2014505470A JP2014505470A JP2014515751A5 JP 2014515751 A5 JP2014515751 A5 JP 2014515751A5 JP 2014505470 A JP2014505470 A JP 2014505470A JP 2014505470 A JP2014505470 A JP 2014505470A JP 2014515751 A5 JP2014515751 A5 JP 2014515751A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- grf analog
- ala
- grf
- arg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 claims 46
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims 46
- 101710142969 Somatoliberin Proteins 0.000 claims 46
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 claims 14
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims 9
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 8
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 8
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 claims 7
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 claims 5
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 claims 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 5
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 4
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 4
- 229960003104 ornithine Drugs 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 238000007920 subcutaneous administration Methods 0.000 claims 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 3
- 125000001431 2-aminoisobutyric acid group Chemical group [#6]C([#6])(N*)C(*)=O 0.000 claims 2
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims 2
- 125000002038 D-arginyl group Chemical group N[C@@H](C(=O)*)CCCNC(=N)N 0.000 claims 2
- 102000018997 Growth Hormone Human genes 0.000 claims 2
- 108010051696 Growth Hormone Proteins 0.000 claims 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 2
- 239000000122 growth hormone Substances 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- -1 trans-3-hexenoyl group Chemical group 0.000 claims 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 1
- PECYZEOJVXMISF-REOHCLBHSA-N 3-amino-L-alanine Chemical compound [NH3+]C[C@H](N)C([O-])=O PECYZEOJVXMISF-REOHCLBHSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- OGNSCSPNOLGXSM-VKHMYHEASA-N L-2,4-diaminobutyric acid Chemical compound NCC[C@H](N)C(O)=O OGNSCSPNOLGXSM-VKHMYHEASA-N 0.000 claims 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161477775P | 2011-04-21 | 2011-04-21 | |
| US61/477,775 | 2011-04-21 | ||
| PCT/CA2012/050242 WO2012142706A1 (en) | 2011-04-21 | 2012-04-17 | Growth hormone releasing factor (grf) analogs and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014515751A JP2014515751A (ja) | 2014-07-03 |
| JP2014515751A5 true JP2014515751A5 (enExample) | 2015-06-11 |
| JP6113144B2 JP6113144B2 (ja) | 2017-04-12 |
Family
ID=47021786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014505470A Expired - Fee Related JP6113144B2 (ja) | 2011-04-21 | 2012-04-17 | 成長ホルモン放出因子(grf)類似体およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8361964B2 (enExample) |
| EP (1) | EP2699591A4 (enExample) |
| JP (1) | JP6113144B2 (enExample) |
| KR (1) | KR20140027284A (enExample) |
| CN (1) | CN103547591A (enExample) |
| AR (1) | AR087727A1 (enExample) |
| BR (1) | BR112013027150A2 (enExample) |
| CA (1) | CA2833434A1 (enExample) |
| MX (1) | MX2013012259A (enExample) |
| WO (1) | WO2012142706A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013190520A2 (en) | 2012-06-22 | 2013-12-27 | The General Hospital Corporation | Gh-releasing agents in the treatment of vascular stenosis and associated conditions |
| PL3445778T3 (pl) | 2016-04-19 | 2021-02-22 | Griffon Pharmaceuticals International Sa | Pegylowane bioaktywne peptydy i ich zastosowania |
| KR20230035600A (ko) * | 2020-07-05 | 2023-03-14 | 쎄러테크놀로지스 인코포레이티드 | Ghrh 유사체의 저-용량 약제학적 조성물 및 이들의 용도 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4518586A (en) | 1983-01-13 | 1985-05-21 | The Salk Institute For Biological Studies | GRF Analogs III |
| US4617149A (en) | 1983-09-21 | 1986-10-14 | Eli Lilly And Company | Growth hormone release factor analogs |
| US4622312A (en) | 1984-09-24 | 1986-11-11 | Hoffmann-La Roche Inc. | Growth hormone releasing factor analogs |
| US4734399A (en) * | 1985-08-06 | 1988-03-29 | Hoffmann-La Roche Inc. | Growth hormone releasing factor analogs |
| US4801456A (en) | 1987-07-09 | 1989-01-31 | International Minerals & Chemical Corp. | Growth hormone-releasing factor analogs |
| EP0307860B1 (en) * | 1987-09-18 | 1994-06-08 | F. Hoffmann-La Roche Ag | Cyclic GRF-analogs |
| NZ237857A (en) * | 1990-04-24 | 1992-05-26 | Lilly Co Eli | Polypeptide compounds with growth hormone releasing factor activity |
| AU662731B2 (en) | 1991-04-09 | 1995-09-14 | F. Hoffmann-La Roche Ag | Growth hormone releasing factor analogs |
| US5262519A (en) | 1991-05-15 | 1993-11-16 | The Salk Institute For Biological Studies | GRF analogs XI |
| WO1996032126A1 (en) | 1995-04-14 | 1996-10-17 | The Administrators Of The Tulane Educational Fund | Analogs of growth hormone-releasing factor |
| PT828758E (pt) | 1995-05-26 | 2002-02-28 | Theratechnologies Inc | Analogos quimericos de corpo gordo-pro-grf com potencia biologica aumentada |
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| EP0922446A1 (en) | 1997-12-03 | 1999-06-16 | Applied Research Systems Ars Holding N.V. | Solution-phase site-specific preparation of GRF-PEG conjugates |
| US6057422A (en) | 1998-11-25 | 2000-05-02 | The Administrators Of The Tulane Educational Fund | Antagonistic analogs of GH-RH inhibiting IGF-I and -II |
| IL155177A0 (en) | 2000-10-05 | 2003-11-23 | Ares Trading Sa | Method for the preparation of grf-peg conjugate |
| CN101696240A (zh) | 2001-02-02 | 2010-04-21 | 康久化学生物技术公司 | 长效生长激素释放因子衍生物 |
| RU2277539C2 (ru) * | 2001-06-08 | 2006-06-10 | Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик С.А.С. | Химерные аналоги соматостатина-дофамина |
| WO2004027064A2 (en) | 2002-09-18 | 2004-04-01 | Centre Hospitalier De L'universite De Montreal (Chum) | Ghrh analogues |
| CA2527039C (en) | 2003-05-29 | 2013-07-09 | Theratechnologies Inc. | Grf analog compositions and their use |
| TW200517400A (en) | 2003-08-05 | 2005-06-01 | Univ Tulane | Antagonistic analogs of GH-RH (2003) |
| EP1675610A4 (en) | 2003-10-20 | 2010-04-28 | Theratechnologies Inc | USE OF GROWTH HORMONE RELEASE FACTOR ANALOGUE IN THE TREATMENT OF PATIENTS WITH EXCEPTION |
| EP1812048A4 (en) | 2004-10-20 | 2012-01-18 | Theratechnologies Inc | GH SECRETAGOGA AND ITS USE |
| US8021859B2 (en) | 2005-03-15 | 2011-09-20 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
| WO2009009727A2 (en) | 2007-07-12 | 2009-01-15 | Akela Pharma Srl | Ghrh analogs and therapeutic uses thereof |
| US20110021429A1 (en) | 2007-10-01 | 2011-01-27 | Pierrette Gaudreau | Renoprotection by growth hormone-releasing hormone and agonists |
| US20100267636A1 (en) | 2009-04-20 | 2010-10-21 | Theratechnologies Inc. | Use of cytochrome p450-metabolized drugs and grf molecules in combination therapy |
-
2012
- 2012-04-17 KR KR1020137030657A patent/KR20140027284A/ko not_active Withdrawn
- 2012-04-17 JP JP2014505470A patent/JP6113144B2/ja not_active Expired - Fee Related
- 2012-04-17 BR BR112013027150A patent/BR112013027150A2/pt not_active IP Right Cessation
- 2012-04-17 CN CN201280024235.3A patent/CN103547591A/zh active Pending
- 2012-04-17 WO PCT/CA2012/050242 patent/WO2012142706A1/en not_active Ceased
- 2012-04-17 MX MX2013012259A patent/MX2013012259A/es active IP Right Grant
- 2012-04-17 CA CA2833434A patent/CA2833434A1/en not_active Abandoned
- 2012-04-17 US US13/448,660 patent/US8361964B2/en not_active Expired - Fee Related
- 2012-04-17 EP EP12774217.9A patent/EP2699591A4/en not_active Withdrawn
- 2012-04-19 AR ARP120101345A patent/AR087727A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013515057A5 (enExample) | ||
| IL262805B1 (en) | CD47 agonist factors for inducing programmed cell death and their use in the treatment of diseases associated with defects in programmed cell death | |
| JP2013515055A5 (enExample) | ||
| TWI374030B (en) | Use of melanocortins to treat insulin sensitivity | |
| FI3482765T3 (fi) | Pitkävaikutteinen kasvuhormoni ja menetelmiä sen tuottamiseksi | |
| JP2013522311A5 (enExample) | ||
| BR122020011001B1 (pt) | Peptídeo derivados de oxintomodulina e seu uso, polinucleotídeo, composição farmacêutica e seu uso e método para prevenção ou tratamento da obesidade compreendendo os mesmos | |
| JP2011511753A5 (enExample) | ||
| JP2005524648A5 (enExample) | ||
| JP2012500001A5 (enExample) | ||
| NZ611878A (en) | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides | |
| JP2013518057A5 (enExample) | ||
| JP2007509984A5 (enExample) | ||
| JP2013517307A5 (enExample) | ||
| AR094180A1 (es) | Derivados de exendina-4 | |
| NZ601818A (en) | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers | |
| JP2014050390A5 (enExample) | ||
| JP2010529957A5 (enExample) | ||
| JP2009191078A5 (enExample) | ||
| HRP20140616T1 (hr) | Peptidni analog oksintomodulina | |
| JP2014530868A5 (enExample) | ||
| RU2013139651A (ru) | Новые соединения, влияющие на пищевое поведение | |
| JP2016518351A5 (enExample) | ||
| JP2013501802A5 (enExample) | ||
| JP2011518179A5 (enExample) |